Angioplasty, stenting, or TIPSS restores blood outflow from the liver when the hepatic veins or vena cava are blocked — a step-up, catheter-based approach that avoids open surgery for most patients.
Budd-Chiari syndrome (BCS) is a condition in which the veins that drain blood out of the liver the hepatic veins, and sometimes the adjoining segment of the inferior vena cava (IVC) — become blocked or narrowed. With outflow obstructed, blood backs up inside the liver, pressure rises in the portal venous system, and the liver becomes congested, which over time can lead to liver damage and, if untreated, cirrhosis.
The blockage is usually caused by blood clots forming within the hepatic veins, often in people with an underlying tendency to clot (a myeloproliferative disorder or another hypercoagulable condition). Less commonly, a web or short-segment narrowing of the vein itself, or external compression from a tumour, cyst, or abscess, is responsible. When another disease process directly causes the obstruction, it's called secondary Budd-Chiari syndrome; when it arises from a primary clotting problem within the vein itself, it's called primary Budd-Chiari syndrome.
Sudden abdominal pain, rapidly developing ascites, an enlarged, tender liver, and sometimes jaundice, over days to a couple of weeks.
A slower build-up of ascites, abdominal swelling, fatigue, and liver enlargement over weeks to months.
A rare, rapidly progressive form with acute liver failure, requiring urgent recognition and treatment.
Blood-thinning medication is started in essentially everyone, usually continued long-term.
For a short-segment narrowing or web in a hepatic vein or the IVC, opened with a balloon and held with a stent.
Creates a new channel through the liver tissue when the hepatic veins are diffusely blocked.
Regular Doppler ultrasound confirms the treated vein or shunt stays open.
Budd-Chiari syndrome is uncommon and can affect people of any age, though it's often identified in younger and middle-aged adults, and is more frequently diagnosed in women, in part because of its association with hypercoagulable states linked to hormonal factors. The presentation depends on how quickly and how completely the outflow is blocked:
Acute presentation — sudden abdominal pain, rapidly developing ascites (fluid in the abdomen), an enlarged, tender liver, and sometimes jaundice, over days to a couple of weeks.
Subacute or chronic presentation — a slower, more insidious build-up of ascites, abdominal swelling, fatigue, and liver enlargement over weeks to months, sometimes with prominent veins visible across the abdomen as the body recruits collateral pathways around the blockage.
Fulminant presentation — a rare, rapidly progressive form with acute liver failure, requiring urgent recognition and treatment.
Because ascites, abdominal pain, and an enlarged liver are common to many liver conditions, Budd-Chiari syndrome can be mistaken early on for more familiar causes of liver disease, especially when the presentation is gradual rather than sudden. It should be specifically considered whenever ascites or unexplained liver dysfunction appears without a clear cause such as viral hepatitis or long-standing alcohol use, particularly in a younger patient or one with a known clotting tendency.
Doppler ultrasound of the liver is usually the first test, and can show absent, reversed, or turbulent flow in the hepatic veins along with a characteristic pattern of intrahepatic collateral vessels. CT or MR venography of the abdomen then maps the site and extent of the blockage more precisely, showing whether one, two, or all three hepatic veins are involved and whether the IVC itself is narrowed. Where intervention is being planned, direct venography and pressure measurements at the time of the procedure confirm the exact anatomy and the pressure gradient across the blockage.
Treatment is tailored to how the blockage is distributed and how the liver is coping, moving in a step-up fashion from the least to the most invasive option that will restore adequate drainage.
Anticoagulation: blood-thinning medication is started in essentially everyone with Budd-Chiari syndrome, both to treat any existing clot and to prevent further clot formation, and is usually continued long-term.
Angioplasty and stenting: when a short-segment narrowing or web is the main problem — in a hepatic vein or in the IVC — a balloon catheter is used to open the narrowed segment, usually followed by placement of a self-expanding metal stent to keep it open long-term. This is done through a needle puncture, typically in the neck or groin vein, without any open incision.
TIPSS (transjugular intrahepatic portosystemic shunt): when the hepatic veins are diffusely blocked rather than narrowed at one point, a TIPSS procedure creates a new channel directly through the liver tissue, connecting the portal vein to a hepatic vein or the IVC, giving blood a fresh route out of the liver and relieving the pressure driving the ascites and congestion. This has become the mainstay of treatment for patients who don't have a focal lesion suitable for simple angioplasty.
Liver transplantation: reserved for patients who reach fulminant liver failure or advanced cirrhosis despite the above measures, or in whom the venous anatomy isn't suitable for angioplasty, stenting, or TIPSS.
Patients generally remain on long-term anticoagulation after angioplasty, stenting, or TIPSS, both to protect the treated vessel or shunt and to manage the underlying clotting tendency that caused the syndrome in the first place. Regular follow-up with liver function tests and periodic Doppler ultrasound is used to confirm the treated vein or shunt stays open, since re-narrowing can occur and may need a repeat procedure. Most patients who are treated before advanced liver damage sets in see substantial improvement in ascites, liver function, and overall symptoms once outflow is restored.
Most commonly, a blood clot forms in one or more of the hepatic veins, often in someone with an underlying tendency to clot. Less often, a web, short-segment narrowing, or external compression of the vein or IVC by a tumour, cyst, or abscess is responsible.
No. Budd-Chiari syndrome is a blockage of the veins draining the liver; if it isn't treated, the resulting congestion can eventually lead to cirrhosis, but the two are different conditions with different starting points.
Not usually. Most patients are managed with anticoagulation plus a catheter-based procedure — angioplasty, stenting, or TIPSS — done through a needle puncture rather than open surgery. Liver transplant is reserved for advanced or fulminant cases.
TIPSS stands for transjugular intrahepatic portosystemic shunt — a new channel created through the liver tissue to connect the portal vein to a hepatic vein or the vena cava, giving blood a route out of the liver when the hepatic veins themselves are diffusely blocked.
Most patients continue anticoagulation long-term, since Budd-Chiari syndrome is usually caused by an underlying clotting tendency that doesn't go away once the blocked vein or shunt is treated.
Book a consultation with Dr. Giragani, or send your scans and reports for a specialist second opinion.